ADAR1 Capital Management’s Cidara Therapeutics CDTX Stock Holding History

ADAR1 Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-59,677	Closed	-$13.2M	–	315
2025 Q4	$13.2M	Buy	59,677 +38,155	+177%	+$6.17M	0.97%	25
2025 Q3	$2.06M	Hold	21,522	–	–	0.19%	78
2025 Q2	$1.05M	Buy	21,522 +584	+3%	+$14K	0.16%	79
2025 Q1	$451K	Sell	20,938 -4,000	-16%	-$88.9K	0.08%	111
2024 Q4	$670K	Buy	+24,938	New	+$405K	0.13%	101

ADAR1 Capital Management's CDTX Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 59,677 shares — an estimated $13.2M sold.

ADAR1 Capital Management first reported a position in CDTX in Q4 2024 and held it in 5 quarters. The position peaked at $13.2M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

ADAR1 Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
ADAR1 Capital Management sold 59,677 Cidara Therapeutics shares in Q1 2026, an estimated $13.2M.
ADAR1 Capital Management first reported a position in Cidara Therapeutics in Q4 2024 and held it in 5 quarters.
ADAR1 Capital Management's Cidara Therapeutics position peaked at $13.2M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.